Ketolide Treatment of Haemophilus influenzae Experimental Pneumonia | Zendy

Kerryl E. Piper | Zendy; Mark S. Rouse | Zendy; James M. Steckelberg | Zendy; Walter R. Wilson | Zendy; Robin Patel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ketolide Treatment of Haemophilus influenzae Experimental Pneumonia

Author(s) -

Kerryl E. Piper,

Mark S. Rouse,

James M. Steckelberg,

Walter R. Wilson,

Robin Patel

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.3.708

Subject(s) - haemophilus influenzae , ketolide , ciprofloxacin , azithromycin , microbiology and biotechnology , clarithromycin , erythromycin , pneumonia , antibacterial agent , biology , medicine , antibiotics

The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producingHaemophilus influenzae isolates were inhibited were 4 and 2 μg/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producingH. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance ofH. influenzae , HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research